Despite advances in cataract surgery, cystoid macular edema (CME) is one of the most common causes of poor visual outcome following cataract surgery.1 Cystoid macular edema is related to the disruption of the blood–retinal barrier (BRB) and blood–aqueous barrier and the inflammation induced by prostaglandins or other inflammatory mediators. Pseudophakic CME typically takes 6 to 8 weeks to develop after cataract surgery. Since the 1970s, topical nonsteroidal antiinflammatory agents (NSAIDs) have been used preoperatively and postoperatively to prevent and treat CME following cataract surgery, but resistant cases of macular edema are common.2 Treatment with periocular steroids or intravitreal steroids can cause increased intraocular pressure (IOP) and glaucoma. 3 We report a patient with refractory pseudophakic CME after uneventful phacoemulsification who underwent intravitreal bevacizumab (Avastin) treatment.

Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.

IACULLI, CRISTIANA;DELLE NOCI, NICOLA
2008

Abstract

Despite advances in cataract surgery, cystoid macular edema (CME) is one of the most common causes of poor visual outcome following cataract surgery.1 Cystoid macular edema is related to the disruption of the blood–retinal barrier (BRB) and blood–aqueous barrier and the inflammation induced by prostaglandins or other inflammatory mediators. Pseudophakic CME typically takes 6 to 8 weeks to develop after cataract surgery. Since the 1970s, topical nonsteroidal antiinflammatory agents (NSAIDs) have been used preoperatively and postoperatively to prevent and treat CME following cataract surgery, but resistant cases of macular edema are common.2 Treatment with periocular steroids or intravitreal steroids can cause increased intraocular pressure (IOP) and glaucoma. 3 We report a patient with refractory pseudophakic CME after uneventful phacoemulsification who underwent intravitreal bevacizumab (Avastin) treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11369/9334
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact